The Cardiologist Said Surgery Was Off the Table. They Did Not Mean This.

There is a category of patient in cardiac medicine that everyone in the field knows and nobody talks about openly: the patient who is too sick for the treatment that would help them most. They have advanced heart failure. Their ejection fraction is dangerously low. The left ventricle is struggling. In a different patient, in better overall shape, a surgical intervention might restore meaningful cardiac function. But the risks of general anesthesia and open-chest surgery are too high. So the surgeon declines, the cardiologist adjusts the medication regimen, and the patient goes home to manage a condition that will keep getting worse.

This is not a rare edge case. Roughly six million Americans live with congestive heart failure today. A significant portion of them are in the category that clinicians call “high surgical risk.” They are older, frailer, or burdened by comorbidities that make the standard surgical pathway genuinely dangerous. For them, “not a surgical candidate” has meant the end of the conversation about intervention. It has meant a future of escalating medications, repeat hospitalizations, and a trajectory that most patients understand without being told directly.

What Made Surgery Risky in the First Place

The risk in open cardiac surgery for advanced heart failure patients is not the idea of the procedure. It is the physical reality of it. General anesthesia for a compromised heart. The trauma of opening the sternum. Cardiopulmonary bypass. A recovery period measured in weeks, during which the patient’s already-stressed system has to manage both the heart failure and the surgical wound. For a 72-year-old with reduced ejection fraction and diabetes, those risks can genuinely outweigh the benefits. The surgeon who declines is making a reasonable call.

The problem is that the reasoning gets generalized. “Surgical candidate” becomes a fixed category. Once a patient is in the no-surgery bucket, the entire class of interventional cardiac therapy gets removed from consideration. The patient is treated as if the only path to intervention requires cracking the chest, when in fact that was never the only path. It was just the only one that existed.

A Different Route to the Same Nervous System

The Harmony™ System, developed by EnoPace, reaches the autonomic nervous system through a catheter. The procedure takes roughly 30 minutes and is performed in a standard cardiac catheterization lab, the same environment used for stent placements and pacemaker installations. There is no sternotomy. No cardiopulmonary bypass. No general anesthesia in most cases. The device navigates through venous access points the body already has, anchors at the target neurostimulation site, and begins modulating the nerve signals that regulate how hard the heart has to work.

That last part matters. Heart failure is not just a problem with the heart muscle. It is also a problem with the nervous system signals that keep demanding more from a muscle that can no longer deliver. The sympathetic nervous system, reacting to the heart’s reduced output, increases heart rate and peripheral resistance to compensate. This compensation works briefly and then accelerates the damage. The heart is asked to work harder precisely when it is least capable of doing so. The Harmony™ System interrupts that cycle. By modulating the autonomic inputs, it reduces the workload on the left ventricle and lets the heart function closer to what it is actually capable of.

The clinical data

 from 12-month follow-up shows measurable hemodynamic improvement in treated patients: reduced LV pressure, improved cardiac output, stabilization of the kind that changes a patient’s daily reality. TCT Congress, the leading interventional cardiovascular conference, awarded the Harmony™ System the #1 Medical Innovation designation in 2025. That is not a participation trophy. TCT evaluates devices across the full spectrum of cardiovascular medicine.

What “Not a Surgical Candidate” Actually Rules Out

A catheter-based neurostimulation procedure and an open-heart operation carry different risk profiles by an enormous margin. The patient population that is too fragile for one is not necessarily too fragile for the other. A high surgical risk patient who cannot tolerate a sternotomy may tolerate a 30-minute catheter procedure under local anesthesia perfectly well. The exclusion that removed surgery from the menu does not automatically exclude this.

This distinction matters most to the patients who have internalized their diagnosis as a sentence rather than a status. When a cardiologist says “surgery is off the table,” most patients hear “intervention is off the table.” For the generation of patients who were diagnosed before transcatheter neuromodulation existed as a clinical category, that interpretation was correct. For patients being evaluated today, it is not.

The conversation about intervention does not have to end with the surgical consult. The question a patient or family member can reasonably ask now is whether the path that was closed was the only one, or just the first one considered. In most cases involving the Harmony™ System, the answer is that a different path exists. Whether it is appropriate for a specific patient is a clinical determination. But the path is there.

Six million Americans with congestive heart failure. A large fraction of them told intervention is not an option. A 30-minute catheter procedure that does not require the surgery they were told was too risky. Those three facts do not resolve neatly, but they do suggest the conversation is not over.